Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zorifertinib First-Line Treatment in EGFR-Mutant NSCLC With CNS Metastases
CTR20254950Phase 4Active
- Sponsor
- Jiangsu Chentai Medical Technology
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of zorifertinib in non-small cell lung cancer (NSCLC), EGFR-mutated non-small cell lung cancer, central nervous system metastases, brain metastases, Carcinomatous Meningitis (CM), sponsored by Jiangsu Chentai Medical Technology. Started Dec 2025; status: active.
02
Drugs
zorifertinib
03
Conditions
non-small cell lung cancer (NSCLC)EGFR-mutated non-small cell lung cancercentral nervous system metastasesbrain metastasesCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on CTR20254950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254950.